Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2026-02-03 @ 9:01 AM
Study NCT ID:
NCT01625260
Status:
TERMINATED
Last Update Posted:
2024-07-19
First Post:
2012-06-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Sponsor:
Altor BioScience
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-muscle Invasive Bladder Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | cancer | View |
| None | immunotherapy | View |
| None | targeted | View |
| None | non-muscle invasive | View |
| None | interleukin-2 | View |
| None | antitumor | View |
| None | TCR | View |
| None | T-cell receptor | View |
| None | p53 | View |
| None | p53 gene | View |
| None | p53 tumor supressor protein | View |
| None | urothelial cancer | View |
| None | bladder cancer | View |
| None | HLA-A2 positive | View |
| None | HLA-A*0201/p53 aa264-272 | View |
| None | HLA complex | View |
| None | refractory | View |
| None | relapsed | View |
| None | BCG | View |
| None | multi-focal | View |
| None | carcinoma in situ | View |
| None | transitional cell carcinoma | View |
| None | gemcitabine | View |